61 results on '"Sugarbaker, Paul H."'
Search Results
52. Guidelenines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society.
- Author
-
Ansaloni, Luca, Andersson, Roland E., Bazzoli, Franco, Catena, Fausto, Cennamo, Vincenzo, Di Saverio, Salomone, Fuccio, Lorenzo, Jeekel, Hans, Leppäniemi, Ari, Moore, Ernest, Pinna, Antonio D., Pisano, Michele, Repici, Alessandro, Sugarbaker, Paul H., and Tuech, Jean-Jaques
- Subjects
- *
COLON cancer , *COLECTOMY , *MORTALITY , *DISEASES , *PERITONEUM surgery - Abstract
Background: Obstructive left colon carcinoma (OLCC) is a challenging matter in terms of obstruction release as well of oncological issues. Several options are available and no guidelines are established. The paper aims to generate evidenced based recommendations on management of OLCC. Methods: The PubMed and Cochrane Library databases were queried for publications focusing on OLCC published prior to April 2010. A extensive retrieval, analyses, and grading of the literature was undertaken. The findings of the research were presented and largely discussed among panellist and audience at the Consensus Conference of the World Society of Emergency Surgery (WSES) and Peritoneum and Surgery (PnS) Society held in Bologna July 2010. Comparisons of techniques are presented and final committee recommendation are enounced. Results: Hartmann's procedure should be preferred to loop colostomy (Grade 2B). Hartmann's procedure offers no survival benefit compared to segmental colonic resection with primary anastomosis (Grade 2C+); Hartmann's procedure should be considered in patients with high surgical risk (Grade 2C). Total colectomy and segmental colectomy with intraoperative colonic irrigation are associated with same mortality/morbidity, however total colectomy is associated with higher rates impaired bowel function (Grade 1A). Segmental resection and primary anastomosis either with manual decompression or intraoperative colonic irrigation are associated with same mortality/morbidity rate (Grade 1A). In palliation stent placement is associated with similar mortality/morbidity rates and shorter hospital stay (Grade 2B). Stents as a bridge to surgery seems associated with lower mortality rate, shorter hospital stay, and a lower colostomy formation rate (Grade 1B). Conclusions: Loop colostomy and staged procedure should be adopted in case of dramatic scenario, when neoadjuvant therapy could be expected. Hartmann's procedure should be performed in case of high risk of anastomotic dehiscence. Subtotal and total colectomy should be attempted when cecal perforation or in case of synchronous colonic neoplasm. Primary resection and anastomosis with manual decompression seems the procedure of choice. Colonic stents represent the best option when skills are available. The literature power is relatively poor and the existing RCT are often not sufficiently robust in design thus, among 6 possible treatment modalities, only 2 reached the Grade A. * Correspondence: mpisano@ospedaliriuniti.bergamo.it 11st Unit of General Surgery, Ospedali Riuniti di Bergamo, Italy Full list of author information is available at the end of the article Ansaloni et al. World Journal of Emergency Surgery 2010, 5:29 http://www.wjes.org/content/5/1/29 WORLD JOURNAL OF EMERGENCY SURGERY © 2010 Ansaloni et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
53. Interstitial pneumonitis following intrapleural chemotherapy.
- Author
-
Zappa, Luis, Savady, Renaldo, Humphries, Gary N., and Sugarbaker, Paul H.
- Subjects
- *
PULMONARY fibrosis , *DRUG therapy , *PHARMACOLOGY , *IMMUNOSUPPRESSIVE agents , *MITOMYCIN C - Abstract
Background: Mucinous neoplasms within the abdomen may disseminate by direct extension through the diaphragm to involve the pleural space. Treatment of this condition is by parietal and visceral pleurectomy followed by hyperthermic intrapleural chemotherapy. Case presentation: In this case report a patient developed persistent right upper lobe interstitial pneumonitis and progressive parenchymal fibrosis following intrapleural chemotherapy treatment with mitomycin C and doxrubicin. The condition persisted until death 28 months later. Death was from progressive intraabdominal disease with intestinal obstruction and sepsis associated with progressive pulmonary parenchymal disease. The right pleural space disease did not recur. Conclusion: This manuscript is the first case report describing interstitial pneumonitis and lung fibrosis following intrapleural chemotherapy. Since pulmonary toxicity from chemotherapy is a dose-dependent phenomenon, dose reduction of intrapleural as compared to intraperitoneal hyperthermic chemotherapy may be necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
54. Prognostic Significance of Histomorphologic Parameters in Diffuse Malignant Peritoneal Mesothelioma.
- Author
-
Cerruto, Carlos A., Brun, Erwin A., Chang, David, and Sugarbaker, Paul H.
- Subjects
- *
MESOTHELIOMA , *TUMORS , *PERITONEAL dialysis , *PROGNOSIS , *PATHOLOGICAL physiology , *THERAPEUTICS - Abstract
Context.—Diffuse malignant peritoneal mesothelioma is currently regarded as a rare and lethal primary tumor arising from the peritoneal membrane. In the past, treatment plans with variable combinations of surgery and systemic chemotherapy were associated with a median survival of approximately 1 year. Standardized treatments using cytoreductive surgery and perioperative intraperitoneal chemotherapy have extended this survival. Objective.—To critically analyze the prognostic significance of histomorphologic parameters as a determinant of survival. Design.—Sixty-two consecutive patients with diffuse malignant peritoneal mesothelioma in whom data were prospectively accumulated were retrospectively analyzed by 14 different histomorphologic parameters. The influences of these pathologic characteristics on survival were critically statistically evaluated. Results.—In a univariate analysis, histologic type, nuclear/ nucleolar size, stroma, depth of invasion into the bowel, atypical mitoses, mitotic index, necrosis, lymph node involvement, and chromatin patterns were found to be significant. In the multivariate analysis, histologic type and nuclear/nucleolar size remained as determinant histomorphologic characteristics. Use of biphasic/sarcomatoid histologic type as a poor prognostic characteristic was limited in that only 8% of patients showed this histology. Conclusions.—Histomorphologic parameters carry prognostic significance in predicting the survival of patients with diffuse malignant peritoneal mesothelioma when treated in a standardized fashion using cytoreductive surgery and perioperative intraperitoneal chemotherapy. Nuclear/ nucleolar size was found to be a reliable histomorphologic assessment available to assess prognosis in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
55. Clinical Perspective on Desmoplastic Small Round-Cell Tumor.
- Author
-
Gil, Alberto, Portilla, Alberto Gomez, Brun, Erwin A., and Sugarbaker, Paul H.
- Subjects
- *
TUMORS , *CANCER cells , *DRUG therapy , *INTRAPERITONEAL injections , *SURGERY - Abstract
Rare diseases are often associated with uninformed medical decisions and poorly executed treatments because of inexperience of the physicians. Desmoplastic small round-cell tumor is a rare disease that is a form of peritoneal surface malignancy usually affecting young males, with a mean survival of 29 months. In order to begin to build a more knowledgeable clinical pathway all 7 patients treated at the Washington Hospital Center were studied and compared to patients described in the medical literature. Clinical and pathological data, tumor distribution, cytoreductive surgery, completeness of cytoreduction and survival were recorded and analyzed. The first most common symptoms were pain, increased abdominal girth and palpable abdominal mass in our patients and in the literature review. The overall survival did not improve with cytoreductive surgery plus intraperitoneal chemotherapy (mean survival 32 months); however, 2 long-term survivors who responded to systemic chemotherapy of 55 and 101 months were recorded. The latter may be the longest survivor reported in the literature. No consistent response to chemotherapy was observed in our patients or in any literature review. Complete surgical removal of this malignancy did not correlate with survival in our patients. The absence of improved survival of our aggressively treated patients as compared to the literature was thought to be a consequence of an advanced stage of the disease. A new comprehensive approach that uses complete clearing of cancer by surgery and perioperative systemic and perioperative intraperitoneal chemotherapy as early as is possible in the natural history of the disease emerged as goals for future management. Copyright © 2004 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
56. Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer
- Author
-
Yonemura, Yutaka, Endou, Yoshio, Bando, Etsurou, Kuno, Kiyoshi, Kawamura, Taiichi, Kimura, Masashi, Shimada, Tsutomu, Miyamoto, Ken-ichi, Sasaki, Takuma, and Sugarbaker, Paul H.
- Subjects
- *
CANCER , *DOCETAXEL , *ANTINEOPLASTIC agents , *ALKALOIDS - Abstract
The effect of intraperitoneal (i.p.) administration of docetaxel was evaluated for preclinical evidence of anticancer activity in athymic mice bearing a gastric cancer cell line, MKN-45-P that shows a high rate of metastasis to the peritoneal cavity of nude mice. Nude mice were inoculated i.p. with 107 MKN-45-P cells. On days 2, 5, 9, 12, 16 and 19 after tumor inoculation, mice were treated with i.p. injection of docetaxel. Treatment doses of docetaxel were 8 mg/kg
(N=7), 2 mg/kg(N=7) and 0.5 mg/kg(N=7). Intraperitoneal carcinoembryonic antigen (CEA) levels, animal body weight, mortality and survival were determined. All control mice developed ascites and died within 19–40 days. The median survival time in the control group was 32 days, while those of mice treated with 8, 2 and 0.5 mg/kg were 90, 63 and 49.5 days, respectively. One of seven mice treated with 8 mg/kg of docetaxel died of toxicity on day 12. Four mice were tumor-free on day 90, but two had tumors in the abdomen when autopsied on day 90. One mouse treated with 2 mg/kg was ascertained to be tumor-free on day 90. All seven mice treated with 0.5 mg/kg of docetaxel died of peritoneal dissemination within 71 days. The results suggest the potential of intraperitoneal docetaxel administration for the treatment of peritoneal dissemination of gastric cancer. [Copyright &y& Elsevier]- Published
- 2004
- Full Text
- View/download PDF
57. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
- Author
-
Mohamed, Faheez, Marchettini, Pierre, Stuart, O. Anthony, and Sugarbaker, Paul H.
- Subjects
- *
PACLITAXEL , *ANTINEOPLASTIC agents , *PHARMACOKINETICS , *ALKALOIDS - Abstract
Background. For cancers that have disseminated to peritoneal surfaces, intraperitoneal chemotherapy administration results in high drug concentration locally with low systemic toxicity. Using a rat model we compared the pharmacokinetics and tissue absorption of paclitaxel infused intraperitoneally in two isotonic carrier solutions: 1.5% dextrose peritoneal dialysis solution (peritoneal dialysis solution) and hetastarch (6% hydroxyethyl starch), a high molecular weight solution. Methods. A total of 60 Sprague Dawley rats were randomized into groups according to the carrier solution administered. Rats were given a single dose of intraperitoneal paclitaxel (40 mg/m2) in 0.1 ml/g body weight of each carrier solution. Each group was further randomized according to the intraperitoneal dwell period (3, 6, 12, 18 and 24 h). At the end of the procedure the rats were killed, the peritoneal fluid was withdrawn completely and the volume recorded. Blood and tissues were sampled using a standardized protocol. Drug concentrations in peritoneal fluid, plasma, and tissues were determined by high-performance liquid chromatography. Results. Fluid clearance from the peritoneal cavity was lower in the presence of hetastarch than in the presence of peritoneal dialysis solution. The mean volumes remaining in the peritoneal cavity were significantly higher with hetastarch at 18 h (P=0.0079). No excess peritoneal fluid remained with peritoneal dialysis solution at 24 h. Mean plasma paclitaxel concentrations were significantly lower with hetastarch at 3 h (P=0.0079), 12 h (P=0.0079), and 18 h (P=0.0317). The mean total quantity of drug remaining in the peritoneal cavity was significantly greater with hetastarch at 12 h (P=0.0079) and 18 h (P=0.0317). There was a 105% increase in the area under the curve ratio of peritoneal fluid to plasma paclitaxel concentrations with hetastarch (391) vs peritoneal dialysis solution (191). Paclitaxel concentrations were significantly greater with peritoneal dialysis solution at 6 h in colon, abdominal wall, and myocardium. Conclusions. The use of intraperitoneal paclitaxel with hetastarch carrier solution provides a pharmacologic advantage for a local-regional killing of residual tumor cells with decreased systemic toxicity. Clinical investigations into the use of 6% hetastarch with high molecular weight chemotherapeutic agents are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
58. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.
- Author
-
de Lima Vazquez, Vinicius, Stuart, O. Anthony, Mohamed, Faheez, and Sugarbaker, Paul H.
- Subjects
- *
PHARMACOKINETICS , *DOXORUBICIN , *ANTHRACYCLINES , *BLOOD plasma - Abstract
Purpose. To measure the clearance intraperitoneal mitomycin C and doxorubicin in patients having peritonectomy and analyze the impact of the extent of peritoneal resection on pharmacokinetics. Methods. A group of 15 patients with peritoneal carcinomatosis were submitted to cytoreductive surgery and heated intraperitoneal chemotherapy. Ten patients received mitomycin C and five, doxorubicin. Six patients underwent total parietal peritonectomy and nine had less-extensive peritonectomy. Pharmacokinetics were determined by sampling peritoneal fluid and blood. Drug concentrations over time, area under the curve ratios and the amount of drug recovered from the peritoneal cavity were calculated and compared between the groups. Results. The concentrations of mitomycin C over time in the peritoneal fluid and plasma were similar in five patients with total parietal peritonectomy as compared to five patients with less-extensive peritonectomy (P=0.5350 and 0.6991; Mann-Whitney test). Mitomycin C area under the curve ratio in total peritonectomy patients was 20.5 and 25.7 in patients with less-extensive peritonectomy. The difference in total amount of drug recovered from the peritoneal cavity was not significant (30.6±6.188% versus 22.6±3.84%, P=0.095). In the studies with doxorubicin, one patient underwent total parietal peritonectomy with similar pharmacokinetics to four patients submitted to partial peritonectomy. Conclusions. The extent of parietal peritoneal resection did not affect the pharmacokinetics of intraoperative intraperitoneal chemotherapy. The pharmacological barrier between the abdominopelvic cavity and plasma is not directly related to an intact peritoneum. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
59. The Characteristics of 206 Long-Term Survivors with Peritoneal Metastases from Colorectal Cancer Treated with Curative Intent Surgery: A Multi-Center Cohort from PSOGI.
- Author
-
Kamada, Yasuyuki, Hida, Koya, Yonemura, Yutaka, Sugarbaker, Paul H., Ghabra, Shadin, Ishihara, Soichiro, Nagata, Hiroshi, Murono, Koji, Goi, Takanori, Katayama, Kanji, Morikawa, Mitsuhiro, Rau, Beate, Piso, Pompiliu, Acs, Miklos, Coccolini, Federico, Canbay, Emel, Hsieh, Mao-Chih, Bhatt, Aditi, Bonnot, Pierre-Emmanuel, and Glehen, Olivier
- Subjects
- *
CANCER patient psychology , *ADJUVANT chemotherapy , *RESEARCH , *ACQUISITION of data methodology , *THERMOTHERAPY , *METASTASIS , *RETROSPECTIVE studies , *INTRAPERITONEAL injections , *CANCER relapse , *MEDICAL cooperation , *COLORECTAL cancer , *PERITONEUM tumors , *COMPARATIVE studies , *MEDICAL records , *DESCRIPTIVE statistics , *CYTOREDUCTIVE surgery , *LONGITUDINAL method , *DISEASE complications - Abstract
Simple Summary: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal metastases from colorectal cancer (CRC). However, the characteristics of long-term survivors are not well documented. This study set out to investigate the patient characteristics associated with the long-term survival of peritoneal metastases from CRC. We retrospectively analyzed 206 long-term survivors who underwent CRS for peritoneal metastases from CRC. We found that most long-term survivors showed low peritoneal cancer index (PCI), low PCI of small bowel subsets, and complete cytoreduction (CC-0), while some exhibited characteristics considered associated with poor prognosis. Background: We conducted this study to review the patient characteristics associated with long-term survival in patients with peritoneal metastases from colorectal cancer who underwent cytoreductive surgery (CRS). Methods: We retrospectively investigated patients with peritoneal metastases from CRC treated with curative intent surgery with or without hyperthermic intraperitoneal chemotherapy at 13 institutions worldwide between January 1985 and April 2015 and survived longer than five years after the first CRS for peritoneal metastases. Clinical and oncological features and therapeutic parameters were described and analyzed. Results: Two hundred six long-term survivors were available for study. The median peritoneal cancer index (PCI) of this cohort was 4 (interquartile range (IQR), 2–7), and the median score of the small bowel regions of the PCI (SB-PCI) was 0 (IQR, 0–2). Complete cytoreduction (CC-0) was achieved in 180 (87.4%) patients. Recurrence was observed in 122 (59.2%) patients at a median of 1.8 (IQR, 1.2–2.6) years. Conclusions: While most long-term survivors showed low PCI/SB-PCI and CCR-0, some had characteristics considered associated with poor prognosis. Curative intent treatments may be considered in well-informed and fit patients showing negative factors affecting survival outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
60. Morbidity and Mortality of Early Postoperative Intraperitoneal Chemotherapy as Adjuvant Therapy for Gastric Cancer.
- Author
-
Wansik Yu, Ilwoo Whang, Averbach, Andrew, Chang, David, and Sugarbaker, Paul H.
- Subjects
- *
STOMACH cancer , *CANCER-related mortality , *DRUG therapy - Abstract
Assesses the morbidity and mortality of early postoperative intraperitoneal chemotherapy (EPIC) in gastric cancer patients. Histopathologic examination; Overall morbidity; Intra-abdominal sepsis without anastomotic leak and bleeding; Minor complications attributable to EPIC; Benefits from adjutant perioperative IC for gastric cancer.
- Published
- 1998
61. Heated Intraoperative Intraperitoneal Mitomycin C and Early Postoperative Intraperitoneal 5-Fluorouracil: Pharmacokinetic Studies.
- Author
-
Jacquet, Pierre, Averbach, Andrew, Stephens, Arvil D., Stuart, O. Anthony, Chang, David, and Sugarbaker, Paul H.
- Subjects
- *
ANTINEOPLASTIC antibiotics , *PHARMACOKINETICS , *MITOMYCIN C , *FLUOROURACIL , *AMINO compounds , *URACIL antagonists - Abstract
Purpose: The purpose of this study was to report the pharmacokinetics of heated intraoperative intraperitoneal mitomycin C (MMC) and to analyze the impact of heat, extent of peritoneal resections, and effect of intraoperative hyperthermic chemotherapy on the pharmacological properties of the peritoneal plasma barrier. Methods: Sixty patients with peritoneal carcinomatosis were included in a phase I/II study combining cytoreductive surgery with 2 h of heated intraperitoneal mitomycin C in an intraoperative lavage technique and one cycle of early postoperative 5-fluorouracil (5-FU) given on postoperative days 1–5. Three pharmacokinetic analyses were performed: (1) pharmacokinetics of heated intraoperative intraperitoneal MMC was determined for 18 patients by sampling peritoneal fluid, plasma, and urine during the 2-h procedure; (2) impact of peritoneal resections on MMC pharmacokinetics was assessed by comparing a group of patients who underwent ≤1 peritonectomy procedure (minimal surgery) to a group of patients who underwent ≥2 peritonectomy procedures (extensive surgery), and (3) effects of heated intraoperative intraperitoneal chemotherapy on the pharmacokinetics of early postoperative intraperitoneal 5-FU by comparing a group of patients treated with heated intraoperative intraperitoneal MMC to a control group who did not receive heated intraoperative intraperitoneal chemotherapy. Results: The mean dose of heated intraoperative intraperitoneal MMC per patient was 22.5 ± 7.1 mg (12.9 ± 3.8 mg/m[sup 2] ). Drug absorption from perfusate was 14.3 ± 2.7 mg. The mean aeras under the curve (AUC) for perfusate and plasma were, respectively, 340 ± 138 and 15 ± 4 µg/ml × min. The mean AUC peritoneal fluid/plasma ratio was 23.5 ± 5.8. Patients who underwent extensive peritoneal resections exhibited a significantly (p = 0.037; Wilcoxon rank test) increased peak plasma concentration of MMC, a significantly (p = 0.029) increased AUC of plasma concentrations and a significantly (p = 0.034) decreased peritoneal fluid/plasma AUC ratio. Pharmacokinetic studies of early postoperative intraperitoneal 5-FU showed no significant difference in plasma AUC, perfusate AUC and AUC ratio between patients who received and those who did not receive heated intraoperative intraperitoneal MMC. Conclusions: Heated intraoperative intraperitoneal chemotherapy achieves high peritoneal concentrations of MMC with limited systemic absorption. Systemic drug absorption during heated intraoperative intraperitoneal chemotherapy is increased when extensive peritoneal resections are performed, but such slight increases are unlikely to change the risk of systemic drug toxicities. Heated intraoperative intraperitoneal chemotherapy does not alter the pharmacokinetics of early postoperative intraperitoneal 5-FU. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.